Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children : SpIDnet observational multicentre study
SpIDnet VE study group; Savulescu, Camelia; Krizova, Pavla; Valentiner-Branth, Palle; Ladhani, Shamez; Rinta-Kokko, Hanna; Levy, Corinne; Mereckiene, Jolita; Knol, Mirjam; Winje, Brita A.; Ciruela, Pilar; de Miguel, Sara; Guevara, Marcela; MacDonald, Laura; Kozakova, Jana; Slotved, Hans Christian; Fry, Norman K.; Nuorti, J. Pekka; Danis, Kostas; Corcoran, Mary; van der Ende, Arie; Vestrheim, Didrik F.; Munoz-Almagro, Carmen; Sanz, Juan Carlos; Castilla, Jesus; Smith, Andrew; Colzani, Edoardo; Pastore Celentano, Lucia; Hanquet, Germaine (2022)
SpIDnet VE study group
Savulescu, Camelia
Krizova, Pavla
Valentiner-Branth, Palle
Ladhani, Shamez
Rinta-Kokko, Hanna
Levy, Corinne
Mereckiene, Jolita
Knol, Mirjam
Winje, Brita A.
Ciruela, Pilar
de Miguel, Sara
Guevara, Marcela
MacDonald, Laura
Kozakova, Jana
Slotved, Hans Christian
Fry, Norman K.
Nuorti, J. Pekka
Danis, Kostas
Corcoran, Mary
van der Ende, Arie
Vestrheim, Didrik F.
Munoz-Almagro, Carmen
Sanz, Juan Carlos
Castilla, Jesus
Smith, Andrew
Colzani, Edoardo
Pastore Celentano, Lucia
Hanquet, Germaine
2022
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202209086954
https://urn.fi/URN:NBN:fi:tuni-202209086954
Kuvaus
Peer reviewed
Tiivistelmä
Background: Pneumococcal conjugate vaccines covering 10 (PCV10) and 13 (PCV13) serotypes have been introduced in the infant immunization schedule of most European countries in 2010–11. To provide additional real-life data, we measured the effectiveness of PCV10 and PCV13 against invasive pneumococcal disease (IPD) in children of 12 European sites (SpIDnet). Methods: We compared the vaccination status of PCV10 and PCV13 serotype IPD (cases) to that of nonPCV13 serotype IPD (controls) reported in 2012–2018. We calculated pooled effectiveness as (1-vaccination odds ratio)*100, and measured effectiveness over time since booster dose. Results: The PCV13 and PCV10 studies included 2522 IPD cases from ten sites and 486 cases from four sites, respectively. The effectiveness of ≥ 1 PCV13 dose was 84.2% (95 %CI: 79.0–88.1) against PCV13 serotypes (n = 2353) and decreased from 93.1% (87.8–96.1) < 12 months to 85.1% (72.0–92.1) ≥ 24 months after booster dose. PCV13 effectiveness of ≥ 1 dose was 84.7% (55.7–94.7) against fatal PCV13 IPD, 64.5% (43.7–77.6), 83.2% (73.7–89.3) and 85.1% (67.6–93.1) against top serotypes 3, 19A and 1, respectively, and 85.4% (62.3–94.4) against 6C. Serotype 3 and 19A effectiveness declined more rapidly. PCV10 effectiveness of ≥ 1 dose was 84.8% (69.4–92.5) against PCV10 serotypes (n = 370), 27.2% (-187.6 to 81.6) and 85.3% (35.2–96.7) against top serotypes 1 and 7F, 32.5% (-28.3 to 64.5) and −14.4% (-526.5 to 79.1) against vaccine-related serotypes 19A and 6C, respectively. Conclusions: PCV10 and PCV13 provide similar protection against IPD due to the respective vaccine serotype groups but serotype-specific effectiveness varies by serotype and vaccine. PCV13 provided individual protection against serotype 3 and vaccine-related serotype 6C IPD. PCV10 effectiveness was not significant against vaccine-related serotypes 19A and 6C. PCV13 effectiveness declined with time after booster vaccination. This multinational study enabled measuring serotype-specific vaccine effectiveness with a precision rarely possible at the national level. Such large networks are crucial for the post-licensure evaluation of vaccines.
Kokoelmat
- TUNICRIS-julkaisut [19816]